Login
$SPRO
$0.93 -$0.02 (1.73%) After hours

$SPRO 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

SP001, an anti-CD40L antibody with potential across multiple immune-mediated diseases, advancing toward Phase 2 initiation in Immunoglobulin G4-related disease (IgG4-RD)

10 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

27 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

28 Aug 2026 8-K: Entry into a Material Definitive Agreement; Other Events

On August 28, 2026, Spero Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale Agreement℠ (the “Sale Agreement”) with Jefferies LLC, as agent (“Jefferies”), pursuant to which the Company may offer ...

12 Aug 2026 8-K: Results of Operations and Financial Condition

Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases

14 Jul 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

On July 8, 2026, Spero Therapeutics, Inc. (the “Company”) entered into a license agreement (the “Innovent Agreement”) with Innovent Biologics (Suzhou) Co., Ltd. and Fortvita Biologics (USA), Inc. (collectively, “Innovent”), pursuant to w...

25 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

The name of the corporation is Spero Therapeutics, Inc. (the “Corporation”).

22 Jun 2026 8-K: Regulation FD Disclosure; Other Events

First and only oral carbapenem antibiotic approved in the US

13 May 2026 8-K: Results of Operations and Financial Condition

New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026

26 Mar 2026 8-K: Results of Operations and Financial Condition

Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025

30 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

19 Dec 2025 8-K: Other Events

On December 19, 2025, Spero Therapeutics, Inc. (the “Company”) announced that its tebipenem HBr development partner, GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”), filed a New Drug Application (“NDA”) resubmission to the ...

13 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Results from PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection (cUTI) presented as IDWeek late-breaker in October 2025

12 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)

18 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

28 May 2025 8-K: Regulation FD Disclosure; Other Events

Spero Therapeutics and GSK Announce PIVOT-PO phase 3 study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee

13 May 2025 8-K: Results of Operations and Financial Condition

Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2 2025

28 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation

CAMBRIDGE, Mass., April 28, 2025 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial inf...

27 Mar 2025 8-K: Results of Operations and Financial Condition

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025

28 Feb 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support